Shree Pacetronix Ltd
Incorporated in 1988, Shree Pacetronix Ltd manufactures and exports Implantable Cardiac Pacemakers.
- Market Cap ₹ 43.2 Cr.
- Current Price ₹ 120
- High / Low ₹ 309 / 115
- Stock P/E 19.4
- Book Value ₹ 37.3
- Dividend Yield 0.00 %
- ROCE 34.7 %
- ROE 29.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.0%
- Debtor days have improved from 96.6 to 77.2 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 24.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6.79 | 8.00 | 6.89 | 7.44 | 6.94 | 6.80 | 7.28 | 8.77 | 7.56 | 9.23 | 20.26 | 22.04 | 19.84 | |
5.53 | 6.60 | 5.86 | 6.37 | 6.39 | 5.88 | 6.50 | 7.57 | 6.62 | 7.45 | 14.81 | 16.16 | 15.38 | |
Operating Profit | 1.26 | 1.40 | 1.03 | 1.07 | 0.55 | 0.92 | 0.78 | 1.20 | 0.94 | 1.78 | 5.45 | 5.88 | 4.46 |
OPM % | 18.56% | 17.50% | 14.95% | 14.38% | 7.93% | 13.53% | 10.71% | 13.68% | 12.43% | 19.28% | 26.90% | 26.68% | 22.48% |
0.04 | 0.01 | 0.03 | 0.02 | 0.05 | 0.01 | 0.17 | 0.04 | 0.05 | 0.07 | 0.10 | 0.14 | 0.15 | |
Interest | 0.42 | 0.47 | 0.42 | 0.37 | 0.40 | 0.32 | 0.32 | 0.38 | 0.35 | 0.29 | 0.30 | 0.45 | 0.47 |
Depreciation | 0.61 | 0.60 | 0.76 | 0.77 | 0.65 | 0.42 | 0.38 | 0.51 | 0.51 | 0.50 | 0.63 | 0.95 | 1.00 |
Profit before tax | 0.27 | 0.34 | -0.12 | -0.05 | -0.45 | 0.19 | 0.25 | 0.35 | 0.13 | 1.06 | 4.62 | 4.62 | 3.14 |
Tax % | 33.33% | 32.35% | -58.33% | 60.00% | -26.67% | 31.58% | 44.00% | 31.43% | 61.54% | 26.42% | 29.44% | 27.49% | |
0.17 | 0.23 | -0.06 | -0.09 | -0.32 | 0.13 | 0.14 | 0.24 | 0.05 | 0.78 | 3.26 | 3.36 | 2.23 | |
EPS in Rs | 0.47 | 0.64 | -0.17 | -0.25 | -0.89 | 0.36 | 0.39 | 0.67 | 0.14 | 2.17 | 9.06 | 9.33 | 6.19 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 25% |
3 Years: | 43% |
TTM: | -17% |
Compounded Profit Growth | |
---|---|
10 Years: | 31% |
5 Years: | 117% |
3 Years: | 307% |
TTM: | -46% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 57% |
3 Years: | 81% |
1 Year: | -61% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 21% |
3 Years: | 29% |
Last Year: | 30% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 |
Reserves | 1.63 | 1.86 | 1.77 | 1.68 | 1.36 | 1.60 | 1.74 | 1.98 | 2.03 | 2.81 | 6.07 | 9.43 | 9.84 |
2.55 | 2.14 | 2.78 | 1.97 | 2.71 | 2.93 | 3.91 | 3.33 | 3.20 | 3.05 | 2.19 | 4.30 | 6.06 | |
1.46 | 1.38 | 0.95 | 1.35 | 1.16 | 1.33 | 1.35 | 2.08 | 2.15 | 2.72 | 4.68 | 4.42 | 5.34 | |
Total Liabilities | 9.24 | 8.98 | 9.10 | 8.60 | 8.83 | 9.46 | 10.60 | 10.99 | 10.98 | 12.18 | 16.54 | 21.75 | 24.84 |
3.56 | 3.42 | 3.13 | 2.55 | 2.02 | 1.88 | 2.40 | 2.47 | 2.69 | 2.56 | 3.12 | 4.24 | 3.85 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.77 | 0.99 | 1.25 | 1.81 | 1.64 | 1.65 | 1.66 | 0.93 | 0.93 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
5.68 | 5.56 | 5.97 | 6.05 | 6.04 | 6.59 | 6.95 | 6.71 | 6.65 | 7.97 | 11.76 | 16.58 | 20.06 | |
Total Assets | 9.24 | 8.98 | 9.10 | 8.60 | 8.83 | 9.46 | 10.60 | 10.99 | 10.98 | 12.18 | 16.54 | 21.75 | 24.84 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.76 | 1.06 | 0.47 | 1.35 | 0.42 | 1.13 | 0.31 | 2.25 | 1.09 | 1.76 | 1.69 | -0.04 | |
-0.34 | -0.44 | -0.49 | -0.18 | -0.86 | -0.52 | -1.01 | -1.00 | -0.53 | -1.19 | -1.41 | -1.67 | |
-0.65 | -0.85 | 0.20 | -1.14 | 0.22 | -0.50 | 0.36 | -1.17 | -0.31 | -0.45 | -1.10 | 1.75 | |
Net Cash Flow | -0.23 | -0.23 | 0.18 | 0.03 | -0.22 | 0.10 | -0.34 | 0.08 | 0.25 | 0.12 | -0.82 | 0.04 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 76.33 | 86.23 | 70.99 | 88.31 | 113.08 | 143.32 | 152.92 | 134.01 | 145.81 | 127.73 | 84.85 | 77.17 |
Inventory Days | 597.81 | 443.76 | 670.58 | 359.32 | 243.33 | 301.93 | 276.44 | 216.62 | 272.02 | 194.20 | 157.41 | 285.83 |
Days Payable | 134.16 | 48.46 | 29.71 | 32.67 | 18.86 | 49.65 | 37.10 | 54.15 | 48.57 | 17.55 | 32.22 | 12.45 |
Cash Conversion Cycle | 539.98 | 481.52 | 711.86 | 414.96 | 337.55 | 395.60 | 392.26 | 296.48 | 369.25 | 304.38 | 210.04 | 350.55 |
Working Capital Days | 183.84 | 179.31 | 235.74 | 197.71 | 216.69 | 209.34 | 217.09 | 129.44 | 159.33 | 120.22 | 96.02 | 163.79 |
ROCE % | 8.81% | 10.53% | 3.56% | 4.16% | -0.80% | 6.46% | 5.06% | 7.93% | 5.30% | 14.43% | 46.15% | 34.74% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
19 Nov - Issuance of duplicate share certificates for Raju Agarwal.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
26 Oct - Issuance of duplicate share certificate requested.
- Submission Of Unaudited Financial Results (Standalone And Consolidated) Along With Limited Review Report For 30.09.2024 19 Oct
-
Board Meeting Outcome for Outcome Of The (03Rd/2024-25) Board Meeting Held On 19Th October, 2024
19 Oct - Approved unaudited financial results for Q2 2024.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Oct - Dear Sir/Ma'am, In accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th September, 2024, based on the …
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Profile:[1][2]
Company deals in 3 major products viz, Pacemakers, Pacing Leads, Pacing System which are further bifurcated as: Ventralite 940+/ Tiranga, Pinnacle-8820, Tiranga -302, Pinnacle-R-SSIR-Model-29, Trinity-R, Smart - E, Atrial-J-Bipolar-Lead-3851-VB, Introducer, Zeus -1, Is1 Bipolar Lead 3851 Vb, Screw-in Lead P12, Pace Maker Analyser, Charak DDDR, Indus I SSB, Implantable Cardioverter Pacemaker, Single Chamber Pacemaker, Reuters Pacemakers, Permanent Pacemaker, Medtronic Pacemaker, Pacing System Analyzer